scispace - formally typeset
Y

Yong Gyu Park

Researcher at Catholic University of Korea

Publications -  277
Citations -  5197

Yong Gyu Park is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: National Health and Nutrition Examination Survey & Hazard ratio. The author has an hindex of 32, co-authored 272 publications receiving 3912 citations. Previous affiliations of Yong Gyu Park include Catholic University College, Kensington & Kyung Hee University.

Papers
More filters
Journal ArticleDOI

Diffusion‐weighted imaging of breast cancer: Correlation of the apparent diffusion coefficient value with prognostic factors

TL;DR: To evaluate the role of diffusion‐weighted imaging (DWI) in the detection of breast cancers, and to correlate the apparent diffusion coefficient (ADC) value with prognostic factors, a large number of patients with known breast cancers are treated with WI.
Journal ArticleDOI

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

TL;DR: A retrospectively reviewed 117 stages Ic-III ovarian cancer patients and suggests that IPHC is a promising new treatment modality in ovarian cancer.
Journal ArticleDOI

Nuclear localization of β-catenin is an important prognostic factor in hepatoblastoma

TL;DR: In this study, mutational and immunohistochemical analyses of beta-catenin were performed in 30 hepatoblastomas, to assess the prevalence of alterations of the Wnt pathway with respect to clinicopathological parameters and survival.
Journal ArticleDOI

Sarcopenia as a Determinant of Blood Pressure in Older Koreans: Findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008–2010

TL;DR: Body composition beyond BMI has a considerable impact on hypertension in elderly Koreans, and subjects with sarcopenic obesity appear to have a greater risk of hypertension than simply obese or sarcopenia subjects.
Journal ArticleDOI

Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.

TL;DR: In advanced ovarian cancer, IPHC using paclitaxel or carboplatin during secondary surgery could be a candidate for regional consolidation therapy to prolong survival and hinder disease progression.